Assessment of serum mid-regional pro-adrenomedullin level in gestational Diabetes Mellitus in Iraqi women

Abstract

Adrenomedullin (ADM) is a strong vasodilator peptide that was first identified in human pheochromocytoma and known to expressed in numerous cell types and believed to have pleiotropic impacts on pregnancy-related vascular adaptations and fetal growth. Mid-regional pro-adrenomedullin (MR-proADM) peptide which secreted in an equimolar concentration to ADM used to quantify ADM in plasma since it has longer half-life with more availability than ADM and for that reason the present study determine the serum MR-proADM level in the plasma of pregnant women with and without GDM and determine any potential correlation between MR-proADM and gestational diabetes mellitus (GDM) in an observational case–control study conducted on 90 pregnant women in the third trimester of pregnancy who were divided into two groups: 45 pregnant women with GDM as patient and 45 apparent healthy pregnant women without GDM as control and the levels of MR-proADM, and the diabetic markers that include fasting serum insulin (FSI), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c) and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) were determined and results revealed that the serum levels of MR proADM were significantly higher in patients with GDM compared with those of controls, and also showed that MR proADM levels were significantly and directly correlated with all studied diabetic parameters which lead to conclude that MR-proADM can serve as prognostic indicator for GDM.

Keywords

• Adrenomedullin
• gestational diabetes
• Mid-regional pro-adrenomedullin
• pregnant women
• insulin resistance
• fasting blood glucose

References

1. [1] markers Faris Raheem M, H Ali S, MA AL-Nuaimi A, G. Shareef L. Impact of serum vitamin D level on selected bone related in obese-type https://doi.org/10.12688/f1000research.126650.1
2. [2] 2 diabetes patients. F1000Res. 2023;12:56. Salman O, Merdaw MA, Almaliky AA. A Novel single nucleotide polymorphism of interleukin-10 gene is linked to Type 2 Diabetes Mellitus in Iraqi patients with Toxoplasmosis. Iraqi J Pharm Sci. 2022;31(Suppl):1-8. https://doi.org/10.31351/vol31issSuppl.pp1-8
3. [3] Mohammed SI, Jasim AL. Genetic polymorphisms associated with diabetic foot ulcer: A review article. Asian J Pharm Pharmacol. 2020; 6(4):298-305. http://dx.doi.org/10.31024/ajpp.2020.6.4.8
4. [4] Sole KB, Staff AC, Laine K. Maternal diseases and risk of hypertensive disorders of pregnancy across gestational age groups. Pregnancy Hypertens. 2021; 25:25-33. https://doi.org/10.1016/j.preghy.2021.05.004
5. [5] Reitzle L, Schmidt C, Heidemann C, Icks A, Kaltheuner M, Ziese T, Scheidt-Nave C. Gestational diabetes in Germany: Development of screening participation and prevalence. J Health Monit. 2021; 6(2): 3-18. https://doi.org/10.25646%2F8325
6. [6] Hu J, Gillies CL, Lin S, Stewart ZA, Melford SE, Abrams KR, Baker PN, Khunti K, Tan BK. Association of maternal lipid profile and gestational diabetes mellitus: A systematic review and meta-analysis of 292 studies and 97,880 women. E-Clin Med. 2021;34:100830. https://doi.org/10.1016/j.eclinm.2021.100830
7. [7] Ozkan H, Topsakal S, Ozmen O. Investigation of the diabetic effects of maternal high-glucose diet on rats. Biomed Pharmacother. 2019;110:609-617. https://doi.org/10.1016/j.biopha.2018.12.011
8. [8] Wani K, Sabico S, Alnaami AM, Al-Musharaf S, Fouda MA, Turkestani IZ, Al-Ajlan A, Alshingetti NM, Alokail MS, Al-Daghri NM. Early-pregnancy metabolic syndrome and subsequent ıncidence in gestational Diabetes Mellitus in Arab women. Front Endocrinol (Lausanne). 2020;11: 98. https://doi.org/10.3389%2Ffendo.2020.00098

9. [9] Wu JN, Gu WR, Xiao XR, Zhang Y, Li XT, Yin CM. Gestational weight gain targets during the second and third trimesters of pregnancy for women with gestational diabetes mellitus in China. Eur J Clin Nutr. 2019;73(8):1155 1163. https://doi.org/10.1038%2Fs41430-018-0358-9
10. [10] Katra P, Dereke J, Nilsson C, Hillman M. Plasma levels of the ınterleukin-1-receptor antagonist are lower in women with gestational Diabetes Mellitus and are particularly associated with postpartum development of Type 2 Diabetes. PLoS One. 2016;11(5):e0155701. https://doi.org/10.1371/journal.pone.0155701
11. [11] Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: A review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:110708. https://doi.org/10.1016/j.biopha.2020.110708
12. [12] Kaufmann RC, Amankwah KS, Dunaway G, Maroun L, Arbuthnot J, Roddick JW Jr. An animal model of gestational diabetes. Am J Obstet Gynecol. 1981;141(5):479-482. https://doi.org/10.1016/s0002-9378(15)33263-4
13. [13] Qiu H, Yu HY, Wang LY, Yao Q, Wu SN, Yin C, Fu B, Zhu XJ, Zhang YL, Xing Y, Deng J, Yang H, Lei SD. Electronic health record driven prediction for gestational Diabetes Mellitus in early pregnancy. Sci Rep. 2017;7(1):16417. https://doi.org/10.1038/s41598-017-16665-y
14. [14] Kim W, Park SK, Kim YL. Gestational diabetes mellitus diagnosed at 24 to 28 weeks of gestation in older and obese Women: Is it too late? PLoS One. 2019;14(12):e0225955. https://doi.org/10.1371/journal.pone.0225955
15. [15] Bequer L, Gómez T, Molina JL, Álvarez A, Chaviano C, Clapés S. Experimental diabetes impairs maternal reproductive performance in pregnant Wistar rats and their offspring. Syst Biol Reprod Med. 2018;64(1):60-70. https://doi.org/10.1080/19396368.2017.1395928
16. [16] Hadi YA, ALlami RH, Suleiman AA. Associations of Epigenetic methylation with vitamin D receptor level in Iraqi Gestational diabetes mellitus patients. J Biotechnol Res Cent. 2023; 17(2):37-43. http://dx.doi.org/10.24126/jobrc.2023.17.2.734
17. [17] Dong Y, Banadakoppa M, Chauhan M, Balakrishnan M, Belfort M, Yallampalli C. Circulating adrenomedullin ıs elevated in gestational Diabetes and ıts role in ımpaired ınsulin production by β-cells. J Clin Endocrinol Metab. 2019;104(3):697-706. https://doi.org/10.1210/jc.2018-01119
18. [18] Dong Y, Betancourt A, Belfort M, Yallampalli C. Targeting adrenomedullin to ımprove lipid homeostasis in diabetic pregnancies. J Clin Endocrinol Metab. 2017;102(9):3425-3436. https://doi.org/10.1210%2Fjc.2017-00920
19. [19] Yao X, Chen X, Adam REH, Zhang Z, Ge Y, Li Y, Huang S, Shi Y, Lv P, Wang S, Zhao R, Hao L, Lu Z, Yang X. Higher serum adrenomedullin concentration is associated with an increased risk of gestational diabetes mellitus: A nested case-control study in Wuhan, China. Nutr Res. 2022;107:117-127. https://doi.org/10.1016/j.nutres.2022.09.004
20. [20] Kato J, Kitamura K, Uemura T, Kuwasako K, Kita T, Kangawa K, Eto T. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res. 2002;25(6):887-892. https://doi.org/10.1291/hypres.25.887
21. [21] Di Iorio R, Marinoni E, Urban G, Costantini A, Cosmi EV, Letizia C. Fetomaternal adrenomedullin levels in diabetic pregnancy. Horm Metab Res. 2001;33(8):486-490. https://doi.org/10.1055/s-2001-16942 [22] Abdualhay RA, Al-Fartosy AJ. Insulin resistance and other adipokines as clinical predictors of gestational diabetes mellitus among pregnant women. Indones Biomed J. 2022; 14(3):243-51. http://dx.doi.org/10.18585/inabj.v14i3.1934
22. [23] Ezeldein ME, Zaky HY, Esihag EM, Mergani A, Elsonni B. Insulin resistance and lipid profiles in pregnancy complicated by gestational diabetes mellitus. Muthanna Med J. 2023; 10(1):105-112. http://dx.doi.org/10.52113/1/1/2023-105-112
23. [24] Iwama N, Sugiyama T, Metoki H, Kusaka H, Yaegashi N, Sagawa N, Hiramatsu Y, Toyoda N; JAGS Group. Difference in the prevalence of gestational diabetes mellitus according to gestational age at 75-g oral glucose tolerance test in Japan: The Japan Assessment of Gestational Diabetes Mellitus Screening trial. J Diabetes Investig. 2019;10(6):1576-1585. https://doi.org/10.1111/jdi.13044.
24. [25] Schaefer-Graf U, Napoli A, Nolan CJ; Diabetic Pregnancy Study Group. Diabetes in pregnancy: a new decade of challenges ahead. Diabetologia. 2018;61(5):1012-1021. https://doi.org/10.1007/s00125-018-4545-y.
25. [26] Kadhim SA, Saleh ES, Jaafer AD. Assessment of serum levels of advanced oxidation protein products in type 2 Diabetic patients with and without retinopathy taking different antidiabetic treatments. Iraqi J Pharm Sci. 2023; 32(2):74-82. https://doi.org/10.31351/vol32iss2pp74-82.
26. [27] Ameen IA, Saleh E, Mhaibes SH, Taha K, Dawood DA, Kamil HS. Evaluation of some inflammatory cytokines and Glycated hemoglobin in uncontrolled type 2 diabetes mellitus with nephropathy. Indian J Forensic Med Toxicol. 2020; 14(2):1628-3227.
27. [28] Sperling M, Grzelak T, Pelczyńska M, Bogdański P, Formanowicz D, Czyżewska K. Association of serum omentin-1 concentration with the content of adipose tissue and glucose tolerance in subjects with central obesity. Biomedicines. 2023;11(2):331. https://doi.org/10.3390/biomedicines11020331.
28. [29] Abdulamir HA, Aldafaay AAA, Al-Shammari AH. The role of liver function tests in monitoring the effect of enzyme replacement therapy in children with Gaucher Disease. Res J Pharm and Tech. 2022; 15(8): 3490–3496. https://doi.org/10.52711/0974-360X.2022.00585
29. [30] Aldafaay AAA, Abdulamir HA, Abdulhussain HA, Badry AS, Abdulsada AK. The use of urinary α-amylase level in a diagnosis of chronic renal failure. Res J Pharm Technol. 2021; 14(3):1597-1600. http://dx.doi.org/10.5958/0974 360X.2021.00283.3